Use of Model‐Based Meta‐Analysis to Inform the Design of Early Clinical Trials of Anti‐Amyloid Beta Therapies in Alzheimer's Disease
ABSTRACT To inform an efficient development of new investigational anti‐amyloid beta (anti‐Aβ) monoclonal antibodies (mAbs), a modeling‐and‐simulation‐based strategy was proposed. A general modeling framework that links drug exposures to the time course of amyloid plaque removal and amyloid‐related...
Saved in:
| Main Authors: | Sagar S. Bachhav, Ana Victoria Ponce‐Bobadilla, Diana Clausznitzer, Sven Stodtmann, Hao Xiong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/psp4.70038 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
by: Alexandra Wicker, et al.
Published: (2024-10-01) -
Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
by: Sha Sha, et al.
Published: (2026-02-01) -
Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species
by: Cynthia J. Siebrand, et al.
Published: (2025-05-01) -
Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
by: Mandić Gorana, et al.
Published: (2008-01-01) -
Immune cell responses to amyloid-beta proteins: What is the extent and implications of amyloid-beta induced cytotoxicity in microglial cells and peripheral blood mononuclear cells?
by: Cao, A.
Published: (2017-07-01)